Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyHIV에 감염되지 않은 건강한 성인을 대상으로 한 두 가지 이종 HIV 백신 요법의 안전성 및 면역원성(TRAVERSE): 무작위 배정, 병렬 그룹, 위약 대조, 이중 맹검, 1/2a상 연구Articles Published on 2020-09-302022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 95% CI Ad26 Adenovirus Administered advancement adverse event adverse events aligned All participant All participants Analysis Antigen antigens applied assigned binding antibodies binding antibody blood sample breadth CD4+ T-cell clade collected computer-generated Defense Deltoid muscle Department diagnosed dose double-blind Efficacy elicit Eligible participants ELISpot responses enrolled finding first vaccination foundation funding group groups healthy Heterologous HIV HIV infection HIV vaccine HIV-1 infection HIV-uninfected IFNγ ELISPOT response IFNγ ELISPOT responses IgG immune response immune responses Immunity immunogenicity injection Intramuscular injection investigator investigators Jackson janssen Laboratory Local magnitude median medical history Medicine Melinda Gate Melinda Gates Military Medicine mononuclear cell mononuclear cells opinion Other parallel-group participant PBMC PBMCs per protocol per-protocol Peripheral blood Peripheral blood mononuclear cells Physical examination Placebo placebo group placebo-controlled placebos prevention randomisation randomised Randomly randomly permuted block randomly permuted blocks regimen regimens Registered repeated risk Safe Safety second vaccination Sponsor stratified subgroups systemic reactogenicity T-cell Response tested tetravalent the placebo group titre titres Tolerability treatment allocation Trial trivalent USA vaccination vaccination schedule Vaccinations Vaccine vaccine group vectored vaccine vital sign was done with HIV [DOI] 10.1016/S2352-3018(20)30229-0 PMC 바로가기 [Article Type] Articles